Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...